1. Home
  2. REED vs TVRD Comparison

REED vs TVRD Comparison

Compare REED & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

REED

Reed's Inc.

N/A

Current Price

$1.60

Market Cap

29.6M

Sector

N/A

ML Signal

N/A

TVRD

Tvardi Therapeutics Inc.

HOLD

Current Price

$2.63

Market Cap

25.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REED
TVRD
Founded
1987
2017
Country
United States
United States
Employees
44
12
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.6M
25.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REED
TVRD
Price
$1.60
$2.63
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$29.50
AVG Volume (30 Days)
19.1K
53.9K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$18.74
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$2.48
52 Week High
$5.97
$43.65

Technical Indicators

Market Signals
Indicator
REED
TVRD
Relative Strength Index (RSI) 29.08 33.20
Support Level N/A N/A
Resistance Level $1.96 $4.20
Average True Range (ATR) 0.22 0.21
MACD 0.03 -0.04
Stochastic Oscillator 11.93 16.75

Price Performance

Historical Comparison
REED
TVRD

About REED Reed's Inc.

Reed's Inc is a branded beverage company offering a portfolio of natural, premium, and functional beverages under the Reed's and Virgil's brands. The company's portfolio of handcrafted, all-natural beverages is sold in outlets nationwide, including the natural and specialty food channel, grocery stores, mass merchants, drug stores, convenience stores, club stores, and on-premise locations, including bars and restaurants. The company operates in a single reportable segment, which consists of manufacturing carbonated beverages under Reed's and Virgil's brand names.

About TVRD Tvardi Therapeutics Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Share on Social Networks: